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A b s t r a c t: The aim of this study is to improve 3-years survival rates and fun-
ctional outcome in high-grade osteosarcoma patients treated with amputations and limb-
sparing surgery, introducing Scandinavian Sarcoma Group chemotherapy protocol (SSG 
XVI). 
 Patients and methods. During the period 2000–2005, thirty seven patients with 
high-grade, non-metastatic osteosarcoma on the extremities were treated at the Clinic 
for Orthopaedic Surgery in Skopje. Mail patients were 21 (57%) and female were 16 
(43%). Patients age varied from 8 to 63 years (mean 18 ± 13). Seven patients (7/37) did 
not comply with including criteria and were excluded from the study. The rest 30 
patients were introduced to two courses of pre-operative chemotherapy (high doses of  
Methotrexate, Cisplatin and Adriamycin). Surgical treatment was in 9-th week of the 
protocol. In 27/30 (90%) of the patients limb-sparing surgery was done, and in 3/30 
(10%) amputations were performed. Histopathological assessment of the tumour after 
the neo-adjuvant chemotherapy divided the patients into group with bad and group with 
good response. All the patients had 3 more courses of chemotherapy after surgery (same 
as the preoperative). Patients with bad response were introduced to 3 more cycles of 5 
days with high-dose of Ifosfamide. Follow-up was from 2 to 8 years, mean 51 months.  
310 Samardziski M., Zafiroski G. et al. 
Results. Histopathological assessment showed that 57% of the patients had bad 
response to neo-adjuvant chemotherapy, but there was no statistical significance in the 
survival time of the groups (p = 0.06). Three-years survival time was 40% of the pati-
ents with local recurrence in comparison with 80% of the patients with no local recur-
rence. Three-years survival time was 20% of the patients with distant metastases in 
comparison with 92% of the patients with no metastases. Overall survival time (OS) 
was 80%. After 3 years 60% of the patients were disease-free (DFS). 
Conclusion. High-grade osteosarcoma of the extremities treated with modern 
chemotherapy protocols enables limb-sparing in the same time with improved survival 
time of the  patients. Introducing high-dose Ifosfamide in treatment of patients with bad 
response after neo-adjuvant chemotherapy improves their functional results as well as 
the survival time. 
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Introduction 
 
Osteosarcoma is a very rare malignant bone tumour with an incidence 
of 4–6 cases in 1,000,000 inhabitants and appears mostly in the young and 
active population aged between 10 and 30. [23] Amputations and disarticula-
tions, the dominant treatment for malignant bone tumours in the beginning of 
20th century, are rarely and very selectively used now. In spite of aggressive and 
radical surgery, the 5-year survival was low (10–20%). [18, 19] The introduc-
tion of new sophisticated diagnostic methods (CT and MRI) gave the possibility 
of precise anatomic definition of the tumours and the borders of infiltration in 
the surrounding tissue. [11] After 1980, improvement of chemotherapeutic pro-
tocols with neo-adjuvant chemotherapy, better preoperative planning and mo-
dern reconstructive options after the resection of osteosarcoma led to better 
survival rates of the patients with limb-sparing procedures. [1, 3, 16, 22] Better 
planning of the biopsy and the definite operative procedure, and fostering better 
patient selection for specific treatment strategies, have decreased the risk of 
spreading the osteosarcoma in surrounding tissue and lowered the risk of distant 
metastases. [6, 18] Currently, 80–85% of the patients with osteosarcoma on the 
extremities can be treated safely with wide resection and limb preservation. [7] 
A multidisciplinary approach to diagnosis and treatment, multimodal chemo-
therapy and a number of options for reconstruction after osteosarcoma resection 
(especially in chemotherapy-sensitive tumours) have increased long-term sur-
vival rates from 60% to 70%. [7, 13, 14, 17]  
 
 
Material and Methods 
 
In the period from 2000–2005, 37 patients with high-grade, extremities-
localized osteosarcoma, were treated at the University Orthopedic Surgery Cli-
nic in Skopje with neo-adjuvant chemotherapy and surgery.  
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Selection of the patients was done according to the following including 
criteria:  
– histopathologically proven high-grade osteosarcoma (grade III or IV),  
– primary localization on the extremities, with no evidence of lung or 
other metastases,  
– patient age between 8 and 65,  
– normal hepatic and renal function,  
– leukocyte range over 3.0 × 109/L and thrombocyte range over 100 × 
109/L,  
– neo-adjuvant chemotherapy introduced no later than 1 month after 
histological  diagnosis of osteosarcoma.  
Excluding criteria for the patients were:  
– patients with central localization of osteosarcoma (eg. pelvis, ver-
tebra),  
– evidence of lymphatic or haematogenous metastases at the time of 
diagnosis,  
– patients younger than 8 or older than 65 years,  
– pregnant or nursing women.  
Diagnosis was made by clinical examination, plane x-rays, CT, MRI 
and histopathologically (with open biopsy). Staging was done with Tc 99m 
bone scans, x-ray of lungs and CT. For preoperative planning MRI and arterio-
graphy were obtained. After completion of the chemotherapy protocol, clinical 
and radiographic evaluation of patients was done every 3 months in the first 
year and twice a year after that. 
Male patients were 21 (57%), and female were 16 (43%). Patients were 
aged from 8 to 63 (mean 18.3 ± 13.4). In 5 (14%) patients osteosarcoma was 
localized on the upper limb and in 32 (86%) it was localized on the lower limb. 
According to the criteria, 7/37 patients were excluded from the study. Twenty-
seven patients were treated with limb-sparing surgery, and 3 patients were trea-
ted with ablative surgery. Patients’ characteristics, due to many clinical attri-
butes, are shown in Table 1.  
All patients were introduced to the Scandinavian Sarcoma Group XIV 
neo-adjuvant chemotherapy protocol (SSG XIV). Patients received 2 cycles of 
preoperative chemotherapy (high dose Methotrexate 1200mg/m2, Cisplatin 
45mg/m2, Adriamycin 75 mg/m2).  
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Table 1 – Tabela 1 
 
Clinical attributes of patients with high-grade osteosarcoma localised  
on extremities, treated with chemoptherapy and surgery 
Klini~ki karakteristiki na pacientite so osteosarkomi  
so visok stepen na malignitet, lokalizirani na ekstremitetite,  
a lekuvani so hemoterapija i hirur{ko otstranuvawe 
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Patients with limb preservation 
1 25 m 0 0 22 30 30 B 83.3 
2 13 m haematom
a 
0 20 25 0 B 60.0 
3 23 m tranzitor.p
arez 
0 0 46 0 B 80.0 
4 16 f 0 0 0 41 0 G 56.7 
5 15 f infection 0 63 68 68 B 46.7 
6 14 m 0 0 0 56 0 G 70.0 
7 13 m 0 0 0 41 0 G 83.3 
8 16 f seroma 0 0 60 0 G 73.3 
9 17 f skin 
necrosis 
6 15 25 25 B 86.7 
10 54 f 0 0 0 43 0 B 63.3 
11 14 f 0 0 0 100 0 G 80.0 
12 63 m 0 0 0 101 0 G 96.7 
13 17 m loosening 0 0 60 0 B 66.7 
14 16 m 0 0 0 64 0 G 96.7 
15 20 f 0 0 51 54 54 B 80.0 
16 20 f 0 0 0 40 0 G 73.3 
17 23 m 0 4 0 42 0 B 33.3 
18 39 f skin 
necrosis 
53 0 66 0 B 83.3 
19 14 m 0 0 0 101 0 G 70.0 
20 8 m 0 0 0 33 0 B 73.3 
21 44 f haematom
a 
0 0 53 0 B 90.0 
22 14 m 0 0 35 40 40 B 83.3 
23 44 f 0 0 0 70 0 G 63.3 
24 15 f 0 0 0 100 0 G 93.3 
25 15 m loosening 2 19 27 27 B 76.7 
26 24 f infection 18 0 28 0 G 56.7 
27 34 m 0 31 0 32 0 B 33.3 
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Patients with amputations 
28 24 m 0 0 0 34 0 G 40.0 
29 13 m seroma 0 0 25 0 B 46.7 
30 15 m seroma 35 43 45 0 B 36.7 
*G – good response after neo-adjuvant chemotherapy (more than 90% of the tumour); B – bad 
response after neo-adjuvant chemotherapy (more than 10% viable tumour)  
** MSTSS – Musculoskeletal Tumour Society score 
 
Figure 1 – Scandinavian Sarcoma Group protocol (SSG XIV)  
for treatment of osteosarcoma 
Slika 1 – Protokolot na skandinavskata grupa za tretman  
na osteosarkomi (SSG XIV) 
 
 
Surgical resection of the osteosarcoma was made 9 weeks after the 
beginning of neo-adjuvant chemotherapy, as shown in Figure 1. After resection, 
a detailed histopathological assessment of the specimen was done to determine 
the extent of necrosis of the tumour tissue. Patients were grouped according to 
the percentage of necrotic tumour tissue. The first group had a good response to 
chemotherapy (> 90% necrosis of the tumour). The second group had a bad res-
ponse to chemotherapy (> 10% viable tumour). According to the "good or bad 
response" of the tumour to chemotherapy, patients were subjected to a different 
"branch" of the protocol (Figure 1). All 30 patients received 3 courses of posto-
perative chemotherapy (the same as preoperative). Patients with bad responses 
received 3 more cycles of chemotherapy with high doses of Ifosfamide (Ifos-
famide 2000 mg/m2 and × 5 days in the cycle).  
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Table 2 – Tabela 2 
 
Enneking’s surgical resection margins 
Enneking-ovite hirur{ki granici pri otstranuvawe na tumor 
Margins of resection Explanation 
Radical resection Resection of the whole anatomical compartment 
Wide borders  
of resection  
Resection of the tumour with 1 to 1.5 cm of surrounding 
tissue 
Marginal borders  
of resection 
Resection is in the vicinity of the tumour, but pseudocapsule 
is not disrupted 
Intratumoural  
resection 
Excision is made through tumour pseudocapsule, 
(no tumour sterility and radicality achieved) 
 
The histopathological assessment of the specimen did not give only the 
extent of tumour necrosis, but also information on tumour-free margins. The 
primary goal was to achieve tumour-free margins. Intralesional resections or 
marginal resections were unacceptable. If this goal was not reached, the extre-
mity was amputated. (Table 2). [9] 
We followed the four basic principles of limb-sparing procedures: 1) local 
recurrence should be no greater and survival no worse than by amputation; 2) the 
procedure, or treatment of its complications, should not delay adjuvant therapy; 3) 
reconstruction should be enduring and not associated with a large number of local 
complications requiring secondary procedures and frequent hospitalization; 4) 
function of the limb should approach that obtained by amputation, although body 
image, patients’ preference and life-style may influence the decision. [21] 
When "negative" tumour margins were obtained, a large skeletal defect 
was often present, requiring reconstruction of the bone, muscles, other soft tis-
sues, and the skin. Patients’ age, tumour location and extent of resection narro-
wed the list of appropriate surgical alternatives. The extent of the disease, ana-
tomical location of the tumour and the patient’s age defined the most appro-
priate surgical procedures.  
Several options for limb-sparing were available:  
– resection arthrodesis and other techniques with special indications 
(Figure 2a, b, c), [2, 4, 8]  
– modular or special expanding endoprostheses (Figure 2d, e, f), [11, 
13, 17] 
– cortico-spongeous or bulk auto-graft (Figure 2g, h, i). [2, 8, 14] 
For the patients who could not satisfy the principles of limb preserva-
tion, ablative surgery was taken into consideratoion. For these patients disarti-
culation of the hip or shoulder griddle, femoral or below knee, humeral or other 
amputations were more appopriate. [4] 
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  a  b  c  
d  e  f    
  g  h  i  
Figure 2 – Various surgical options for limb-sparing: a, b, c) x-rays and MRI of tibial 
osteosarcoma treated with resection arthrodesis (temporary or first stage procedure); d, e, f) 
x-rays and CT of osteosarcoma patient with distal femur and knee special endoprosthesis 
reconstruction (Link); g, h, i) x-rays and MRI of proximal humerus osteosarcoma treated 
with vascularised cortico-spongeous graft (fibula) and osteosynthesis 
Slika 2 – Razli~ni hirur{ki tehniki za za~uvuvawe na ekstremitetite: 
a, b, c) radiografija i magnetna rezonansa na tibijalen osteosarkom 
tretiran so resekcija i artrodeza na kolenoto (kako privremena ili 
procedura vo prv akt); d, e, f) radiografija i kompjuterska tomografija 
na pacient so osteosarkom, kaj koj e napravena rekonstrukcija na dolniot 
del od butnata koska i kolenoto so specijalna tumorska endoproteza 
(tip Link); g, h, i) radiografija i magnetna rezonansa na osteosarkom 
lokaliziran na gorniot del od nadlakotnata koska, koja po hirur{koto 
otstranuvawe e rekonstruirana so vaskulariziran  
kortiko-spongiozen presadok (od fibula) i osteosinteza 
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A Musculosceletal Tumour Society score (MSTSS), based on Enne-
kings’ system for functional evaluation of reconstructive procedures, was used 
to determine the functional results. [10] This score system evaluates: pain, fun-
ction, patient’s emotional acceptance (pertinent to the patient as a whole) and 
specific factors for evaluating upper limb (range of motion, manual dexterity 
and lifting ability) or lower limb (need of support with orthopaedic accesories, 
ability to walk, and gait). For each of six factors, values from 0 to 5 are assig-
ned, with a total of 30 (or 100% function of the limb). For each factor, values 1, 3 
and 5 are equated with criteria levels of achievement or performance. Interme-
diate values of 2 or 4 are assigned, based on the examiner’s judgment, when ac-
hievement or performance falls between the specified values. It is recomended 
that results be reported numerically in percentages of normal function (Table 1).  
The cumulative prospect of 3 years overall survival (OS) was calculated 
using the Kaplan-Meier method. [15] The statistical significance of the diffe-
rences between the survival curves was evaluated using the Log-Rank test and 
the generalised Wilcoxon test, with the criteria of probability being less than 
0.05.  
Follow-up was 2 to 8 years, mean 51.7 (± 23.6) months. Results were 
updated in December 2007. 
 
 
Results 
 
Thirty patients (30/37) included in the study were divided into two 
groups: 27 with limb-sparing and 3 with ablative surgery (Table 2).  
Histopathological assessment showed a bad response to neo-adjuvant 
chemotherapy in 57% of the patients (17/30). In the group of patients with a bad 
response, 75% survived for 36 months, and in the group with a good response 
100% of the patients survived 36 months (as shown in Figure 3). Statistical ana-
lysis showed no significance between the groups (Log-Rank test = 1.87 p = 0.06). 
Five patients (5/30) or 16.7% developed local recurrence between 2 and 
36 months after surgery. In the group of patients with local recurrence 40% 
survived for 36 months, and in the group without local recurrence 88% of the 
patients survived 36 months (as shown in Figure 4). Statistical analysis showed 
a high significance (Log-Rank test = –2.48 p = 0.013).  
Five patients (5/30), or 16.7%, developed distant metastases from bet-
ween 15 to 36 months after surgical treatment. Only 20% survived for 36 
months in the group of patients with metastases, compared to the group of 
patients without metastases, where 92% of the patients survived 36 months (as 
shown in Figure 5). Statistical analysis showed high significance (Log-Rank test 
= 3.7 p = 0.0002).  
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Figure 3 – Cumulative proportion surviving according to response after neo-adjuvant 
chemotherapy. (Group 0 – patients with bad response, group 1 – patients with good 
response) 
Slika 3 – Vkupno pre`ivuvawe na pacientite spored odgovorot  
na neo-adjuvantnata hemoterapija. (Grupa 0 – pacienti so lo{ odgovor  
na hemoterapijata, grupa 1 ‡ pacienti so dobar odgovor) 
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       Figure 4 – Cumulative proportion of surviving according local recurrence 
(Group 0 – patients without local recurrence, group 1 – patients with local recurrence) 
Slika 4 – Vkupno pre`ivuvawe na pacientite spored pojavata na lokalni 
recidivi. (Grupa 0 – pacienti bez lokalen recidiv, grupa 1 ‡ pacienti  
so lokalen recidiv) 
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Figure 5 – Cumulative proportion surviving according to distant metastases.  
(Group 0 – patients without metastases, group 1 – patients with metastases) 
Slika 5 – Vkupno pre`ivuvawe na pacientite spored pojavata  
na oddale~eni metastazi. (Grupa 0 ‡ bez oddale~eni metastazi,  
grupa 1 ‡ so oddale~eni metastazi) 
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Figure 6 – Kaplan-Meier survival curve 
Slika 6 – Kaplan-Meier-ovata kriva na pre`ivuvawe na pacientite 
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Ten patients (10/27) with limb-preserving surgery (37.0%) had compli-
cations. In 3 patients (3/27) with limb-sparing (11%), complications or local 
recurrence led to secondary ablative surgery. All three patients (10%) with 
primary amputations were male. One of them had prolonged seroma and anot-
her one, due to local recurrence, was reamputated.  
The three-year overall survival was 80% (Figure 6). In our study, 18 pa-
tients (18/30) are disease-free after 3 years (60%), with no significant statistical 
difference between good or bad responders (Log-Rank test = 1.87 p = 0.06).  
Functional results (MSTS score) after rehabilitation showed approxi-
mately 65% function of the spared upper limbs and 76% function of the spared 
lower limbs (Table 2). 
 
 
Discussion 
 
Amputations, once a dominant treatment for malignant bone tumours, 
are rarely and very selectively used now. Most patients with extremity-localized 
osteosarcoma are candidates for limb-sparing procedures because of effective 
chemotherapeutic agents and regimens, improved imaging modalities and ad-
vances in reconstructive surgery. Various options for skeletal reconstructions 
include modular endoprostheses, ostearticular or bulk allografts, arthrodeses, 
expandable endoprostheses, rotationplasty and limb-lengthening techniques. 
Two primary goals must always be considered: survival rates should be no 
worse than those associated with amputation and the reconstructed limb must 
provide satisfactory function. [1, 7, 10, 11, 13] 
However, surgical treatment associated with limb-sparing procedures is 
also associated with significant complications and requires extensive rehabi-
litation [7]. 
Before consideration of limb preservation, the patient needs to be ap-
propriately staged and assessed through a multidisciplinary approach [9]. Some 
elements of the disease may warrant concern, including relative contraindica-
tions to such procedures [6]. During the past few decades neo-adjuvant chemo-
therapy has made dramatic advances in the treatment of nonmetastatic osteosar-
coma of the extremities [1]. Multidrug neoadjuvant therapy, popularized for 
patients with osteosarcoma by Rosen in the late 1970s, is usually initiated as ap-
propriate after pathohistological diagnosis and staging. Neoadjuvant chemothe-
rapy dramatically improves long-term survival rates in patients with osteosar-
coma sensitive to chemotherapy. [1, 3, 18, 22] Introducing the Scandinavian 
Sarcoma Group XIV chemotherapy protocol equalizes survival rates between 
"good" and "bad" responders. [1, 3, 21] Patients considered operable at diagno-
sis or following neo-adjuvant chemotherapy (9 weeks after beginning of the 
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neoadjuvant chemotherapy) must undergo "wide margins" resection of the 
osteosarcoma. Patients with a bad response received 3 more cycles of chemo-
therapy with a high dose of Ifosfamide (Ifosfamide 2000 mg/m2 and × 5 days in 
the cycle). The main risk of limb-salvage procedures is that complications may 
sometimes cause a delay in the chemotherapy regimen. If the basic principles of 
limb-sparing surgery and “tumour sterility and radicality” are not to be achie-
ved, amputation is a better choice than limb preservation at any cost [18].  
The three-year overall survival (OS), disease-free survival (DFS) and 
functional results (MSTS score) of the patients in our study are comparable to 
the results published in the literature [1, 7, 12, 13, 17]. There was no significant 
difference in 3-year overall survival between the groups of "bad" and "good" 
responders to chemotherapy (p = 0.06). A comparison of results of patients with 
limb-sparing and amputations in our study with the results of patients with 
surgery at our Clinic in the period prior to 2000 comes out in favour of the 
group treated with neo-adjuvant chemotherapy.    
 
 
Conclusion 
 
The application of neo-adjuvant chemotherapy followed by limb-
salvage surgery calls for responsible, trained and highly engaged medical staff. 
Introducing a high dose of Ifosfamide for "bad responders" to preoperative 
chemotherapy improves the results and overall survival of the patients. If treat-
ment and management principles of high-grade osteosarcoma are followed, 
limb-sparing with 60–70% survival rates and improved functional results could 
be achieved. Our preliminary results are promising and encouraging. 
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A p s t r a k t: Celта na ovoj trud e zgolemuвawe na trigodi{noto 
vreme na pre`ivuvawe i podobruvawe na funkcionalnite rezultati, kaj pa-
cientite so osteosarkom so visok stepen na malignitet na ekstremitetite, 
tretirani so hemoterapiskiot protokol na skandinavskata sarkoma grupa 
broj XIV i operativna intervencija. 
Pacienti i metodi: Vo ovoj trud bea analizirani 37 pacienti so 
osteosarkom na ekstremitetite, so visok stepen na malignitet, tretirani 
vo periodot od 2000 do 2005 godina na Klinikata za ortopedski bolesti vo 
Skopje. Od niv 21 (57%) bea ma`i i 16 (43%) bea `eni. Vozrasta se dvi-
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`e{e od 8 do 63 godini (sredno 18,3 ± 13,4). Sedum pacienti (7/37) bea isklu-
£eni od analizata, bidejќi ne gi ispolnuvaa potrebnite kriteriumi. Osta-
natite 30 pacienti primija dva ciklusi na predoperativna hemoterapija 
(visoki dozi na Methotrexat, Cisplatin, Adriamycin). Hirur{koto lekuvawe se 
извршуваше vo devettata nedela od protokolot. Kaj 27 (90%) pacienti se 
извршija operacii za spasuvawe na ekstremitetite, a kaj 3 (10%) amputacii. 
Patohistolo{kaта analiza na izvadeniot tumor gi podeli pacientite vo 2 
grupi: pacienti so dobar odgovor na hemoterapijata i pacienti so lo{ od-
govor. Site pacienti imaa u{te 3 ciklusi na postoperativna hemoterapija 
(ista kako i predoperativnata). Pacientite so lo{ odgovor na hemoterapi-
jata dobija u{te 3 ciklusi od po 5 dena so visoka doza Ifosfamide. Sledeweto 
na pacientite be{e od 2 do 8 godini ili sredno 51 mesec.  
Rezultati: Patohistolo{kata analiza otkri lo{ odgovor na neo-
adjuvantnata hemoterapija kaj 57% od pacientite, no nema{e statisti£ki 
zna£itelna razlika vo pre`ivuvaweto na grupite (p = 0,06). Trigodi{noto 
pre`ivuvawe na pacientite so lokalen recidiv be{e 40% vo sporedba so 
88% na tie bez recidiv. Trigodi{noto pre`ivuvawe na pacientite so odda-
le£eni metastazi be{e 20% vo sporedba so 92% na tie bez metastazi. Vkup-
noto trigodi{no pre`ivuvawe (OS) be{e 80%. Po tri godini od lekuvaweto 
(DFS), 60% od pacientite bea bez metastazi i lokalni recidivi. 
Zaklu£ok: Modernata hemoterapija kaj pacientite so osteosarkom 
so visok stepen na malignitet, lokaliziran na ekstremitetite, dava mo`-
nost za za£uvuvawe na ekstremitetot i istovremeno go prodol`uva vremeto 
na pre`ivuvawe. Vklu£uvaweto na visoki dozi na Ifosfamide kaj pacientite 
so lo{ odgovor na predoperativnata hemoterapija, gi podobruva rezulta-
tite i go prodol`uva vremeto na pre`ivuvawe. Na{ite po£etni rezultati 
se ohrabruva£ki. 
 
Klu£ni zborovi: osteosarkom, neoadjuvantna hemoterapija, spasuvawe na 
ekstremiteti. 
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